Tech Company Financing Transactions
bluebird bio Funding Round
On 7/25/2012, bluebird bio raised $60 million in Series D investment from Deerfield Capital, RA Capital and Shire Pharmaceuticals.
Transaction Overview
Company Name
Announced On
7/25/2012
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds will be used to advance the company's clinical programs in severe genetic disorders, including childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia and sickle cell disease.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
60 Binney St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nick Leschly
Chief Financial Officer
Jeffrey Walsh
Chief Medical Officer
David Davidson
Chief Scientific Officer
Philip Gregory
Chief Technical Officer
Derek Adams
VP - Bus. Development
Joanne Smith-Farrell
VP - General Counsel
Jason Cole
VP - Human Resources
Kathy Wilkinson
Browse more venture capital transactions:
Prev: 7/25/2012: LiveStar venture capital transaction
Next: 7/25/2012: Ticketfly venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs